Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacy-based Study on the Effectiveness, Tolerability, Usage Behavior and User Satisfaction of Iberogast® in Functional and Motility-related Gastrointestinal Diseases, Preferably Irritable Bowel Syndrome.

NCT04993989 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04993989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04993989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacy-based Study on the Effectiveness, Tolerability, Usage Behavior and User Satisfaction of Iberogast® in Functional and Motility-related Gastrointestinal Diseases, Preferably Irritable Bowel Syndrome.
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
November 16, 2017
Completion date
April 18, 2018
Enrollment
843 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

functional and motility related gastrointestinal disorders such as irritable bowel syndrome and functional dyspepsia